399 related articles for article (PubMed ID: 9129866)
21. New strategies in the treatment of infectious complications in haematology and oncology: is there a role for out-patient antibiotic treatment of febrile neutropenia?
Karthaus M; Carratalà J; Jürgens H; Ganser A
Chemotherapy; 1998; 44(6):427-35. PubMed ID: 9755304
[TBL] [Abstract][Full Text] [Related]
22. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors.
Kebudi R; Görgün O; Ayan I; Gürler N; Akici F; Töreci K
Med Pediatr Oncol; 2001 Apr; 36(4):434-41. PubMed ID: 11260566
[TBL] [Abstract][Full Text] [Related]
23. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.
Moghnieh R; Estaitieh N; Mugharbil A; Jisr T; Abdallah DI; Ziade F; Sinno L; Ibrahim A
Front Cell Infect Microbiol; 2015; 5():11. PubMed ID: 25729741
[TBL] [Abstract][Full Text] [Related]
24. Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.
Park JR; Coughlin J; Hawkins D; Friedman DL; Burns JL; Pendergrass T
Med Pediatr Oncol; 2003 Feb; 40(2):93-8. PubMed ID: 12461792
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic value of PCR analysis of bacteria and fungi from blood in empiric-therapy-resistant febrile neutropenia.
Nakamura A; Sugimoto Y; Ohishi K; Sugawara Y; Fujieda A; Monma F; Suzuki K; Masuya M; Nakase K; Matsushima Y; Wada H; Katayama N; Nobori T
J Clin Microbiol; 2010 Jun; 48(6):2030-6. PubMed ID: 20392911
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of predictors of adverse outcome in febrile neutropenic episodes in pediatric oncology patients.
Bothra M; Seth R; Kapil A; Dwivedi SN; Bhatnagar S; Xess I
Indian J Pediatr; 2013 Apr; 80(4):297-302. PubMed ID: 23255077
[TBL] [Abstract][Full Text] [Related]
27. Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment.
Vento S; Cainelli F
Lancet Oncol; 2003 Oct; 4(10):595-604. PubMed ID: 14554236
[TBL] [Abstract][Full Text] [Related]
28. Combating infections in neutropenic patients.
Pizzo PA
Hosp Pract (Off Ed); 1989 Jul; 24(7):93-100, 103-4, 107-10. PubMed ID: 2501330
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey.
Agaoglu L; Devecioglu O; Anak S; Karakas Z; Yalman N; Biner B; Eryilmaz E; Goksan B; Unuvar A; Agirbasli H; Can M; Bilgen H; Gedikoglu G
J Chemother; 2001 Jun; 13(3):281-7. PubMed ID: 11450887
[TBL] [Abstract][Full Text] [Related]
30. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy.
Erjavec Z; de Vries-Hospers HG; Laseur M; Halie RM; Daenen S
J Antimicrob Chemother; 2000 Jun; 45(6):843-9. PubMed ID: 10837439
[TBL] [Abstract][Full Text] [Related]
31. [Antibiotic therapy in leukopenia].
Böhme A; Shah PM; Stille W; Hoelzer D
Praxis (Bern 1994); 1998 Sep; 87(36):1120-5. PubMed ID: 9782739
[TBL] [Abstract][Full Text] [Related]
32. Outpatient oral antibiotics for febrile neutropenic cancer patients.
Ouvrier MJ; Thery JC; Blot E
J Clin Oncol; 2006 Dec; 24(35):5614; author reply 5614-5. PubMed ID: 17158551
[No Abstract] [Full Text] [Related]
33. Piperacillin-tazobactam and netilmicin as a safe and efficacious empirical treatment of febrile neutropenic children.
Le Guyader N; Auvrignon A; Vu-Thien H; Portier E; Tabone MD; Leverger G
Support Care Cancer; 2004 Oct; 12(10):720-4. PubMed ID: 15138864
[TBL] [Abstract][Full Text] [Related]
34. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.
Freifeld A; Marchigiani D; Walsh T; Chanock S; Lewis L; Hiemenz J; Hiemenz S; Hicks JE; Gill V; Steinberg SM; Pizzo PA
N Engl J Med; 1999 Jul; 341(5):305-11. PubMed ID: 10423464
[TBL] [Abstract][Full Text] [Related]
35. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients.
Cagnoni PJ; Walsh TJ; Prendergast MM; Bodensteiner D; Hiemenz S; Greenberg RN; Arndt CA; Schuster M; Seibel N; Yeldandi V; Tong KB
J Clin Oncol; 2000 Jun; 18(12):2476-83. PubMed ID: 10856108
[TBL] [Abstract][Full Text] [Related]
36. [The use of teicoplanin in neutropenic patients: values and limits].
Espinouse D; Chomarat M
Pathol Biol (Paris); 1990 Jun; 38(5 ( Pt 2)):552-6. PubMed ID: 2143573
[TBL] [Abstract][Full Text] [Related]
37. A prospective study of cefepime versus ticarcilline/clavulanate as empirical treatment of febrile neutropenia in lymphoma patients.
Naseem A; Hussain Y; Ahmad B; Aziz MT; Ahmad M; Hameed H
J Pak Med Assoc; 2011 Jan; 61(1):18-22. PubMed ID: 22368896
[TBL] [Abstract][Full Text] [Related]
38. Empirical therapy for bacterial infections in neutropenic patients.
Klastersky J
Support Care Cancer; 1994 Nov; 2(6):347-54. PubMed ID: 7858926
[TBL] [Abstract][Full Text] [Related]
39. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century.
Sipsas NV; Bodey GP; Kontoyiannis DP
Cancer; 2005 Mar; 103(6):1103-13. PubMed ID: 15666328
[TBL] [Abstract][Full Text] [Related]
40. [Changes in the epidemiology of infections in patients with febrile neutropenia].
Karthaus M; Carratala J
Wien Med Wochenschr; 2001; 151(3-4):47-52. PubMed ID: 11789419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
